Vectormune ND
Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
Gebrauchsinformation
(PIL)
15-02-2024
Fachinformation
(SPC)
15-02-2024
Öffentlichen Beurteilungsberichts
(PAR)
10-04-2018
Wirkstoff:
cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain
Verfügbar ab:
CEVA-Phylaxia Co. Ltd.
ATC-Code:
QI01AD
INN (Internationale Bezeichnung):
Newcastle disease and Marek’s disease vaccine (live recombinant)
Therapiegruppe:
Chicken; Embryonated eggs
Therapiebereich:
Immunologicals for aves, Live viral vaccines
Anwendungsgebiete:
For active immunisation of 18 day-old embryonated chicken eggs or one-day-old chicks to reduce mortality and clinical signs caused by Newcastle disease virus and to reduce mortality, clinical signs and lesions caused by Marek’s disease virus with a phenotype "virulent".
Produktbesonderheiten:
Revision: 7
Berechtigungsstatus:
Authorised
Berechtigungsdatum:
2015-09-08
Gebrauchsinformation
OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Up-to-date information on this veterinary medicinal product is
available on the Veterinary Medicines
Information website.
Lesen Sie das vollständige Dokument
Fachinformation
OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Up-to-date information on this veterinary medicinal product is
available on the Veterinary Medicines
Information website.
Lesen Sie das vollständige Dokument
